date:Jul 20, 2012
n for Alzheimers patients.
Nestle said the stake in Accera will allow the collection of more extensive clinical data to support existing research into Axona.
Nestles Health Sciences investment will enable us to expand our clinical development program and strengthen our commercial capabilities in the U.S., said Holger Kunze, president and c.e.o. of Accera. Longer term, it will also give us the opportunity to enlarge the geographic footprint of Axona.